Rational Design of Antibiotics Targeted at the Ribosome

Information

  • Research Project
  • 6948879
  • ApplicationId
    6948879
  • Core Project Number
    R44AI051104
  • Full Project Number
    5R44AI051104-03
  • Serial Number
    51104
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/15/2002 - 22 years ago
  • Project End Date
    11/30/2006 - 18 years ago
  • Program Officer Name
    PETERS, KENT
  • Budget Start Date
    9/1/2005 - 19 years ago
  • Budget End Date
    11/30/2006 - 18 years ago
  • Fiscal Year
    2005
  • Support Year
    3
  • Suffix
  • Award Notice Date
    8/2/2005 - 19 years ago

Rational Design of Antibiotics Targeted at the Ribosome

[unreadable] DESCRIPTION (provided by applicant): Rapid and widespread emergence of antibiotics-resistant pathogens creates an urgent need for concerted approaches towards novel antiinfectives. The long-term objective of this proposal is the development of novel potent antibacterials that target the ribosomal RNA (rRNA) of antibiotics-resistant bacteria. Specifically, a lead series of small molecules that recognize the ribosomal decoding-site RNA (A-site) will be developed to select an antibacterial drug candidate by iterative rounds of synthesis and testing for target binding, inhibition of protein synthesis and bacterial growth. The ribosomal A-site constitutes a prime target for antibiotics, validated by the naturally occurring aminoglycosides and a novel series of chemically unrelated antibacterials that we have discovered recently. Rational structure-based design along with multi-dimensional drug optimization, using testing data from a range of biochemical and biological assays, will allow us to develop a novel class of antibiotics that are not susceptible to known bacterial resistance mechanisms. These novel antibacterial A-site ligands will constitute the first class of antibiotics that has been developed by a rational approach of drug discovery specifically directed at an RNA component of the bacterial ribosome. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    633600
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:633600\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ANADYS PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    92121
  • Organization District
    UNITED STATES